|Therapeutic monoclonal antibody|
|Mol. mass||145531.5 g/mol|
|Metabolism||Unknown, possibly reticuloendothelial system.|
|Half life||2-12 days|
WikiDoc Resources for
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Trastuzumab (more commonly known under the trade name Herceptin) is a humanized monoclonal antibody that acts on the HER2/neu (erbB2) receptor. Trastuzumab's principal use is as an anti-cancer therapy in breast cancer in patients whose tumors over express (produce more than the usual amount of) this receptor. Trastuzumab is administered either once a week or once every three weeks intravenously for 30 to 90 minutes.
Mechanism of action
Amplification of ErbB2 occurs in 25-30% of early-stage breast cancers. It encodes the transmembrane tyrosine kinase p185-erbB2 glycoprotein. Although the signaling pathways induced by the erbB2 receptor are incompletely characterized, it is thought that activation of the PI3K/Akt pathway is important. This pathway is normally associated with mitogenic signaling involving the MAPK pathway. However in cancer the growth promoting signals from erbB2 are constitutively transmitted — promoting invasion, survival and angiogenesis of cells. Furthermore overexpression can also confer therapeutic resistance to cancer therapies. The prime mechanism that causes increase in proliferation speed is due to induction of p27Kip1, an inhibitor of cdk2 and of cell proliferation, to remain in the cytoplasm instead of translocation in to the nucleus. This is caused by phosphorylation by Akt.
Trastuzumab is a humanized monoclonal antibody which binds to the extracellular segment of the erbB2 receptor. Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there is reduced proliferation. It has been suggested that trastuzumab induces some of its effect by downregulation of erbB2 leading to disruption of receptor dimerization and signaling through the downstream PI3K cascade. P27Kip1 is then not phosphorylated and is able to enter the nucleus and inhibit cdk2 activity, causing cell cycle arrest. Also, trastuzumab suppresses angiogenesis by both induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of erbB2 that results in the release of the extracellular domain. Trastuzumab has been shown to inhibit erbB2 ectodomain cleavage in breast cancer cells. There may be other undiscovered mechanisms by which trastuzumab induces regression in cancer.
Predicting response to therapy
The initiation of trastuzumab therapy is based upon the identification of HER-2 overexpression. Various methodologies have been developed to identify overexpression of HER-2. In the routine clinical laboratory, the most commonly employed methods are immunohistochemistry (IHC) and either chromogenic or fluorescent in situ hybridisation (CISH/FISH). In addition numerous PCR-based methodologies have also been described.
Routine HER-2 status is performed by IHC, and there are currently two FDA-approved commercial kits available; Dako Herceptest and the Ventana Pathway. These are highly standardised, semi-quantitative assays which stratify expression levels into; 0 (<20,000 receptors per cell, no visible expression), 1+ (~100,000 receptors per cell, partial membrane staining, < 10% of cells overexpressing HER-2), 2+ (~500,000 receptors per cell, light to moderate complete membrane staining, > 10% of cells overexpressing HER-2), and 3+ (~2,000,000 receptors per cell, strong complete membrane staining, > 10% of cells overexpressing HER-2). The presence of cytoplasmic expression is disregarded. Treatment with trastuzumab is indicated in cases where HER-2 expression has a score of 3+. However, IHC has been shown to have numerous limitations, both technical and interpretative, which have been found to impact on the reproducibility and accuracy of results, especially when compared with ISH methodologies. It is also true, however, that some reports have stated that IHC provides excellent correlation between gene copy number and protein expression.
Fluorescent in situ hybridization (FISH) is viewed as being the “gold standard” technique in identifying patients who would benefit from trastuzumab. It is, however expensive, and requires a fluorescent microscope and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies between CISH and FISH have shown that these two techniques show excellent correlation. The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH.
Currently the recommended assays are a combination of IHC and FISH, whereby IHC scores of 0 and 1+ are negative, scores of 3+ are positive, and scores of 2+ and 2+/3+ are refereed to FISH for definitive diagnosis.
Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer". The combination of Trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to Trastuzumab alone.
It is possible to determine the "erbB2 status" of a tumour, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumour is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab. It is surprising that although erbB2 has great affinity for the receptor and the fact that such a high dose can be administered (due to its low toxicity) 70% of patients do not respond to treatment. In fact resistance is developed rapidly by treatment, in virtually all patients. It is suggested that a mechanism of resistance is the lack of p27Kip1 translocation to the nucleus in some strains, enabling cdk2 to induce cell proliferation.
Some recent clinical trials have found trastuzumab reduces the risk of relapse in breast cancer patients by 50% when given in the adjuvant setting (i.e. after breast cancer surgery, before the cancer has spread any further) for one year.
In one British trial this translated as follows: 9.4% of those on the drug relapsed as opposed to the 17.2% of those not on trastuzumab. In this study, almost five out of six patients would not have developed a recurrence during the study whether or not they received trastuzumab, and almost one in ten patients relapsed despite it and therefore received no apparent benefit from the treatment. Only one patient in 13 received positive benefit in terms of cancer recurrence. However, these numbers solely consider the risk of a cancer recurrence and do not account for morbidity and mortality (sickness and death) due to the treatment's side effects.
Even among the 20% of first-time breast cancer patients for whom trastuzumab is an appropriate treatment, the actual net benefits are not overwhelming when viewed in terms of all-cause mortality. All-cause mortality helps balance a reduced risk of death from cancer against the increased risk of death from a treatment's side effects. Repeated, large-scale studies show that it is usually necessary to treat between 25 and 100 patients to prevent a single death during the next two to four years., For each life saved, between ten and 25 patients will develop heart disease; despite effective treatments, some of these patients will die from heart disease. For example, in the N9831 (arm C) and NSABP B31 joint analysis, approximately two patients died of excess heart disease or other complications for every three lives saved by reducing breast cancer.  The excess heart disease induced by the drug explains why it is necessary to treat up to 100 cancer patients to save a single life during a two-year study period.
The media have sometimes misrepresented trastuzumab as a "cure all" or "wonder drug" and this has caused confusion amongst women with breast cancer about whether they should be receiving the drug or not. 
Optimal duration of adjuvant trastuzumab
The optimal duration of adjuvant trastuzumab is currently unknown. One year of treatment is generally accepted as the ideal length of therapy based on current clinical trial evidence that demonstrated the superiority of one year treatment over none.  However, a small Finnish trial also showed similar improvement with nine weeks' of treatment over no therapy. Due to the lack of direct head to head comparison in clinical trials, it is unknown whether a shorter duration of treatment may just be as effective (with less side effects) than the current accepted practice of treatment for one year. Debate about treatment duration has become a relevant issue for many public health policy makers due to the high financial costs involved in the administration of this treatment for one year. Some countries with a free public health system such as New Zealand, has opted to only fund for nine weeks of adjuvant therapy as a result. Current clinical trials are in progress hoping to answer this question by directly comparing short versus long duration of therapy. 
One of the significant complications of trastuzumab is its effect on the heart. Trastuzumab is associated with cardiac dysfunction in 2-7% of cases. Approximately 10% of patients are unable to tolerate this drug because of pre-existing heart problems; physicians are balancing the risk of recurrent cancer against the higher risk of death due to cardiac disease in this population. The risk of cardiomyopathy is increased when trastuzumab is combined with anthracycline chemotherapy (which itself is associated with cardiac toxicity).
The biotech company Genentech gained FDA approval for trastuzumab in September 1998. The drug was jointly developed by that company, where the antibody was first discovered by scientists that included Dr. Axel Ullrich, and the Jonsson Cancer Center at UCLA, where Dr. Dennis Slamon subsequently worked further on trastuzumab's development.
In the clinical trials leading up to trastuzumab's approval, 42% of patients taking trastuzumab in combination with the chemotherapy drug paclitaxel had significant responses. The comparable rate for the taxane alone was only 16%. Common side effects of the infusion to trastuzumab were commonly fever, chills, pain, fatigue, nausea, vomiting and headache
Trastuzumab costs about seventy thousand US dollars for a full course of treatment. Recently there has been controversy in New Zealand and the UK about public health funding of this drug in the adjuvant setting due to its high cost and perceived limited overall survival (though not breast cancer-free survival). The campaign waged by cancer victims to get the governments to pay for their treatment has gone to the highest levels in the courts and the cabinet to get it licensed against the judgement of the regulator. After a sustained campaign from cancer sufferers, the Ontario Ministry of Health in July 2005 decided that it would pay for treatments with trastuzumab and two other new and controversial anti-cancer drugs.
Few reporters have questioned the pricing of this drug but when asked, Genentech refuses to give details to explain the high costs.
Since October 2006 trastuzumab has been made available for Australian women with early stage breast cancer via the public benefits scheme. This is estimated to cost the country over $1 million Australian. However, the women concerned are ecstatic and many more can now take the benefit of this drug who could not afford to before (some were selling everything in order to pay around $70 000 Australian on average for the year). When trastuzumab was introduced in the UK there was considerable variation in availabity between different geographical regions. Scotland was first to make the drug widely available - other areas eventually followed suit - but many women were prompted to launch legal actions against their local health authority in an effort to be treated with the drug.
- Bange, J; Zwick E, Ullrich A. (2001). "Molecular targets for breast cancer therapy and prevention". Nature Medicine 7: 548 – 552. PMID 11329054.
- Ménard, S; Pupa SM, Campiglio M, Tagliabue E (2003). "Biologic and therapeutic role of HER2 in cancer". Oncogene 22: 6570 – 6578. PMID 14528282.
- Kute, T; Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP (2004). "Development of herceptin resistance in breast cancer cells". Cytometry 57A: 86 – 93. PMID 14750129.
- Albanell, J; Codony J, Rovira A, Mellado B, Gascon P. (2003). "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4". Advances in Experimental Medicine and Biology 532: 253 – 268. PMID 12908564.
- Tan, AR; Swain SM (2002). "Ongoing adjuvant trials with trastuzumab in breast cancer". Seminars in Oncology 30 (5 Suppl 16): 54 – 64. PMID 14613027.
- Nahta, R; Esteva1 FJ (2003). "HER-2-Targeted Therapy – Lessons Learned and Future Directions". Clinical Cancer Research 9: 5078 – 5048. PMID 14613984.
- Yu, D; Hung M (2000). "Overexpression of ErbB2 in cancer and ErbB2-targeting strategies". Oncogene 19: 6115 – 6121. PMID 11156524.
- Romond, EH; Perez EA, Bryant J, et al. (2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". New England Journal of Medicine 353: 1673 – 1684. PMID 16236738.
- Piccart-Gebhart MJ, MJ; Procter M, Leyland-Jones B, et al. (2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". New England Journal of Medicine 353: 1659 – 1672. PMID 16236737.
- Littlejohns, P (2006). "Trastuzumab for early breast cancer: evolution or revolution?". Lancet Oncology 7 (1): 22 – 3. PMID 16408378.
- Herceptin Benefits and Risks.
- Misleading press coverage of trastuzumab.
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006). "Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer". N Engl J Med 354 (8): 809-20. PMID 16495393.
- Metcalfe, S; Evans J, Priest G. (2007). "PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.". N Z Med J 120: 1U2593. PMID 17589560.
- Fleck L. "The costs of caring: Who pays? Who profits? Who panders?". Hastings Cent Rep 36 (3): 13-7. PMID 16776017.
- Breast cancer drug to remain unfunded. New Zealand Herald (2006-10-16). Retrieved on 2006-12-01.
- The trastuzumab judgement. BBC News (2006-04-12). Retrieved on 2006-12-01.
- Update on Herceptin appraisal. National Institute for Health and Clinical Excellence. Retrieved on 2006-12-01.
- Ontario to pay for cancer drugs. Canadian Broadcasting Corporation (2005-07-22). Retrieved on 2006-12-01.
- Will Herceptin Media Blitz Help Or Harm Patients?. Scoop (2006-02-14). Retrieved on 2006-12-01.
- Bazell, Robert. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998. 214 pages. ISBN 0-679-45702-X.
- The Guardian. The selling of a wonder drug. 29 March 2006
- Herceptin (manufacturer's website)
Humanized monoclonal antibodies ("-zu-")
|"-tuzu-" (tumor)||Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin|
|"-lizu-" (immune system)||Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab|
|"-cizu-" (cardiovascular)||Bevacizumab, Tadocizumab|
|"-neuzu-" (nervous system)||Bapineuzumab|
|"-toxazu-" (toxin as target)||Urtoxazumab|
|"-vizu-" (viral infections)||Felvizumab, Motavizumab, Palivizumab, PRO 140|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies